Bedrosian Camille L (CIK 1326969) reported 12 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2026-09-14). Recent activity: Sell AMLX (7,947 shares), Sell AMLX (2,081 shares), Sell CRNX (16,300 shares), Sell CRNX (5,925 shares), Buy AMLX (22,807 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-14 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | Sell | 7,947 | $256,004 |
| 2026-09-14 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | Sell | 2,081 | $68,864 |
| 2026-09-01 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Sell | 16,300 | $1.4M |
| 2026-09-01 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Sell | 5,925 | $503,625 |
| 2026-08-20 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | Buy | 22,807 | $0 |
| 2026-06-22 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Buy | 5,925 | $0 |
| 2026-03-09 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | Buy | 95,990 | $0 |
| 2026-03-04 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | Sell | 6,461 | $94,201 |
| 2025-12-03 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | Sell | 6,580 | $94,423 |
| 2025-10-02 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | Sell | 12,039 | $175,529 |
| 2025-06-23 | RHYTHM PHARMACEUTICALS, INC. (RYTM) | Director | Buy | 4,000 | $0 |
| 2025-06-13 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Buy | 6,900 | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-09-14